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Abstract
Obesity is becoming a silent worldwide epidemic, with a steady increase in both
adults and children. To date, even though several drugs have been licensed for long‐
term obesity treatment, none of them are yet used in routine clinical practice. So far
the only successful intervention has been behavioral therapy. A suitable and eco-
nomic experimental model mimicking the human condition would therefore be
extremely useful to evaluate preventive measures and novel treatments. Zebrafish
are emerging as an important model system to study obesity and related metabolic
disease. Remarkable similarities have been reported in lipid metabolism and the adi-
pogenic pathway between zebrafish and mammals. Moreover, the zebrafish pos-
sesses a number of features—the relative inexpensiveness of animal husbandry, its
optical transparency and the ability to produce a large number of offspring at low
cost—that make it ideal for large‐scale screening and for testing drugs and interven-
tion. In this review, we summarize recent progress in using zebrafish as a model sys-
tem to study obesity and obesity‐related metabolic disorders. We describe several
zebrafish models (in both larvae and adult animals) that develop obesity and non‐
alcoholic fatty liver disease (NAFLD) using different approaches, including gene
manipulation, diet manipulation and modification of microbiota composition. For
these models, we have outlined the specific aspects related to obesity and its devel-
opment and we have summarized their advantages and limitations.
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1 | INTRODUCTION
Over the past decade, obesity has been increasingly recognized as
silent public health problem, becoming an epidemic in many coun-
tries throughout the world.1 Obesity can be defined as an excess of
body fat. It is typically measured by body mass index (BMI)
expressed as kg/m2.2 Using the BMI system, people are classified as
overweight (BMI ≥ 25) and obese (BMI ≥ 30). Obesity is a conse-
quence of a prolonged imbalance between introduced calories and
energy expenditure. The resultant energy surplus is stored as lipid
droplets throughout the body, in both adipose and non‐adipose tis-
sues. Several data indicate that a “junk dietary pattern,” involving
individual genetics, lifestyle and “junk” food consumption, and excess
caloric intake contribute to the increased occurrence of obesity andFrancesca Faillaci and Fabiola Milosa contributed equally to this work.
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obesity‐related diseases.3,4 The current recommendations for the
treatment of obese people include lifestyle modification, increasing
physical activity and reduction of caloric intake. Pharmacotherapy can
be considered if these interventions are ineffective. Food and Drug
Administration (FDA)‐approved drugs for the treatment of obesity are
currently 5: bupropion‐naltrexone, liraglutide, lorcaserin, orlistat, and
phentermine‐topiramate. However, the consistent number of adverse
effects still discourages their routine clinical use.5
The pathogenesis of obesity is not completely clear. It involves pro-
cesses far more complex than the passive accumulation of fat excess
throughout the body.6,7 Adipose tissue (AT) responds rapidly and
dynamically to an excess of nutrients through adipocyte hypertrophy
and hyperplasia. Systemic physiology reacts to AT changes with modi-
fication of endocrine and metabolic functions. In particular, AT remod-
eling has been investigated to clarify the relationship among pro‐
inflammatory adipocytokines, cytokines and obesity‐associated meta-
bolic disorders.8 Macrophages play a main role as the immune cells
responsible for AT inflammation. Obesity induces a phenotype switch
in macrophage polarization and increases secretion of pro‐inflamma-
tory molecules such as tumor necrosis factor‐α (TNFα), interleukin‐6
(IL‐6) and monocyte chemoattractant protein‐1 (MCP‐1).8-10 In addi-
tion, the interaction between adipocytes and macrophages results in
marked down‐regulation of anti‐inflammatory adipocytokines. The
process leads to development of obesity‐related complications in mul-
tiple organs,11 that is a progressive increase in the risk of metabolic
disorders like insulin resistance, type 2 diabetes mellitus (T2DM), car-
diovascular diseases, stroke, and several types of cancer.11,12
Several metabolic studies have revealed that the regional distri-
bution of fat within the body is more relevant than the total amount
of body fat in predicting the development of obesity‐related comor-
bidities.13,14 In particular, the amount of visceral adipose tissue
(VAT) and the ectopic deposition of fat are critically correlated with
elevated risk of development of cardiovascular and metabolic disor-
ders.14 These obesity‐related disorders are commonly known as
metabolic syndrome and are present in the majority of obesity
cases.15 Plasmatic free fatty acids (FFAs) released by increased AT in
obese patients form an important link between obesity and meta-
bolic syndrome.16 Increased flux of FFAs to the liver and muscle pro-
motes lipotoxicity, alters insulin action and leads to non‐alcoholic
fatty liver disease (NAFLD), a spectrum of liver tissue changes rang-
ing from steatosis to non‐alcoholic steatohepatitis (NASH), cirrhosis
and hepatocellular carcinoma.4
It is therefore of the greatest importance to develop a suitable
and economic experimental model that enables investigations of the
pathogenic mechanisms of obesity and evaluation of drug interven-
tions. Over the past few decades, several animal models have pro-
vided a fundamental contribution to our understanding of the
genetic and nutritional factors that regulate the expansion of AT in
the obesity condition. Among these models, Danio rerio (zebrafish) is
emerging as important vertebrate system in which to study obesity
and related metabolic disease, to discover and investigate the origin
and progression of these conditions, and to test new potential drugs
aimed at modulating the pathways involved. As a model for
biomedical research, including considerations of economy of animal
husbandry and rapidity of biological events, the zebrafish is a power-
ful instrument that reflects several anatomic, genetic and functional
features of mammals.17 Moreover, the similarity between the cellular
anatomy of zebrafish adipocytes and mammalian AT and the pres-
ence of all key organs required in lipid metabolism makes it an ideal
tool to study adipogenesis, obesity and metabolic disease.18,19
Furthermore, in zebrafish, microbiota can be easily modulated. As in
mammals, microbiota have been shown to have an important role in
obesity and obesity‐related diseases. For all these reasons, several
models of obesity and metabolic disease have been developed in
zebrafish, which have led to the identification of genes of interest
and to the evaluation of drugs with potential to regulating lipid
metabolism and AT accumulation (Figure 1).
2 | IN VIVO APPROACH TO STUDYING
OBESITY IN ZEBRAFISH LARVAE
2.1 | Lipid staining
To better understand the alterations in the physiology of an organ-
ism caused by obesity, the zebrafish model can be used to trace the
origin of adipogenesis, from egg fertilization to larval state. In mam-
mals, there are two main classes of AT: brown adipose tissue (BAT),
which dissipates energy and generates heat, and white adipose tis-
sue (WAT), designed for energy storage and regulation of energy
balance. Unfortunately, the mechanisms involved in their develop-
ment and regulation are still unclear20 due in part to difficulties asso-
ciated with imaging AT in mammalian model systems, especially
during early life stages.
Zebrafish larvae, developing outside the mother's body and being
optically transparent, are suitable tools for the microscopic and bio-
chemical study of lipid transport and for screening defects in lipid
uptake, transport, and disposition. Indeed, lipid metabolism, obesity,
cardiovascular damage, and metabolic diseases have been exten-
sively studied in this model.17,21 Zebrafish possess all specialized cell
types involved in lipid absorption and processing (eg intestinal ente-
rocytes, fat‐storing adipocytes, hepatocytes in the liver, and acinar
cells of the pancreas).22,23 Adipocytes can be visualized in developing
zebrafish larvae with various dyes, such as the sudanophilic dye Oil
Red O (ORO), Sudan, Nile Red or Lipid Green.24 To assess fatty acid
mobilization and transport, the lipophilic BODIPY® fluorophore is
used: when injected into the zebrafish yolk, it rapidly diffuses within
3 hours into the circulatory system.25
Zebrafish larvae start to eat at 5‐6 days post‐fertilization (dpf); dur-
ing this period, they absorb essential fat‐soluble vitamins, triacylglycerol
(TAG) and cholesterol provided by a maternally derived yolk sac.26 At
the 5 dpf larvae stage, lipids are present in many tissues, including a
minor accumulation in hepatocytes. The first signs of adipogenesis
become visible at 8 dpf in the visceral cavity close to the pancreas. Adi-
pocytes also appear in 12 dpf larvae in the pancreas.26
Using Nile Red staining, adipocytes are clearly visible at 15 dpf
in the visceral region (intra‐abdominal and surrounding internal
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organs),20 a localization associated in humans with more adverse risk
factors for developing T2DM.27,28 The number of adipocytes is cor-
related with size of the larvae rather than age, suggesting body‐
length dependent lipid storage in adipocytes. Whereas at 17 dpf, all
larvae have WAT in the pancreatic and visceral area, at 20‐22 dpf
they develop, in a size‐dependent manner, subcutaneous (SL > 8.2
mm) and cranial (SL > 9.4 mm) adipocytes.29
Lipid staining allows monitoring of dietary lipid absorption fol-
lowing a high‐fat liquid feeding protocol in zebrafish larvae: after
incubation for 1 hour in a 4% solution of fat (containing heavy whip-
ping cream) the anterior intestine and inter‐segmental vessels of 6
dpf larvae exhibited strong staining with ORO. The increase in the
level of ORO staining correlated with whole‐larval TAG.
2.2 | In situ hybridization and mRNA markers of
obesity
In response to a single high‐fat meal, microsomal triglyceride transfer
protein (mtp) mRNA levels increase in the proximal intestine and
liver, but the protein level remains unchanged.30 Marza and collabo-
rators31 reported that MTP protein with 54% identity with human
MTP is present in zebrafish. Using in situ hybridization and RT‐PCR,
they confirmed developmental regulation and tissue specificity of
mtp expression during early embryogenesis and in anterior intestine
and liver from 48 hpf onward. MTP is involved in lipoprotein assem-
bly into nascent ApoB. The complex ApoB‐MTP‐lipoproteins is able
to prevent the degradation of lipids by proteasomes and to increase
plasma lipid levels. As expected, ApoB levels increased in response
to feeding.32,33 All the evidence mentioned above suggests that
WAT distribution in zebrafish larvae and its regulation have a con-
served molecular basis with humans.34 The process of adipogenesis
has been well studied and most master regulators have been identi-
fied: teleost adipocytes express genes associated with lipid metabo-
lism such as fatty acid binding protein 11a (FABP11A), peroxisome
proliferator‐activated receptor gamma (PPARG), and CCAAT/enhancer
binding protein alpha (CEBPA),23,30,34-36 and adipocyte endocrine
function (LEPTIN and ADIPONECTIN).30,36-38 In particular, the
FABP11A protein plays an important role in maintenance of glucose
and lipid homeostasis as well as angiogenesis.39 PPARs are regula-
tors of lipid metabolism, with an important role in energy release
through lipid breakdown.36 PPARG is involved in lipid storage and
adipogenesis, and also in differential regulation of insulin resistance
and glycemic control.40 Pparγ mRNA is expressed early in zebrafish
development (5‐10 hpf). The transcription factor C/EBPα seems to
F IGURE 1 Zebrafish models of obesity
and obesity‐related disease. Several
different approaches, including diet‐
induced obesity (blue), and mutant (green)
and transgenic (red) models, are used in
zebrafish to study the pathways involved
in obesity development and progression.
Proadipogenic and antiadipogenic
pathways are described and used in order
to characterize this condition at the
molecular level. Increased adipose tissue
(AT) causes a rise in free fatty acids (FFAs)
that determines ectopic fat deposition and
inflammation. Both phenomena collaborate
in inducing obesity‐related diseases.
Microbiota dysbiosis is involved by
promoting obesity development and
inflammation. Transgenic models of lipid
accumulation in the liver, which resemble
the human condition, were also developed
in zebrafish but they failed to induce
obesity
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control PPARG expression. These factors drive adipocyte differentia-
tion. In zebrafish, cebpα mRNA is clearly expressed in both visceral
and pancreatic WAT, and, interestingly, in unfertilized eggs.30
A recent study reported, for the first time, that the transcription
factor SOX6 acts as an activator of adipogenesis upstream of PPARG
and mesoderm specific transcript (MEST) by direct binding to their
promoters. The basic functions of SOX6 in adipogenesis are con-
served between humans and other vertebrates, as shown in vivo in
sox6 homozygous null‐mutant larvae of zebrafish. These findings are
an important step in investigating a hypothetical direct role of the
fetal origins of human obesity and its postnatal development.41
2.3 | Gene manipulation to follow gene expression
in vivo
One of the major advantages of zebrafish is the simplicity and effi-
ciency of manipulation of gene expression. Mutant and transgenic
fish, in which gene expression has been deregulated, allow in vivo
studies at a molecular level of the pathway involved in diseases.
Moreover, transgenic zebrafish larvae can express fluorescent pro-
teins in specific cell types, which are then easily detected in the
transparent larvae, enabling monitoring of obesity development and
progression. Furthermore, zebrafish embryos and larvae up to 5 dpf
are not subject to the same regulatory requirements as adult mam-
mals, increasing the value of this high‐throughput instrument.
Using transgenes (Table 1), eg, zebrafish Tg(hPPARγ-eGFP)42
incorporating green fluorescent protein (GFP) under regulatory con-
trol of the gene of interest, it is possible to monitor live tissues and
to investigate specific drug actions. An interesting study conducted
in this model has tested the obesogenic potential of chemicals that
we are exposed to on a daily basis in our environment, evaluating
lipid accumulation and its correlation to their capacity to activate
PPARG in zebrafish larvae.43
Recently, several studies reported a key role of macrophages in
adipose tissue inflammation. Different molecules involved are identi-
fied, but the underlying mechanism still remains unclear. The zebra-
fish macrophage reporter line Tg(lyz:Ds Red) has been used to study
macrophage infiltration into adipose tissue in zebrafish.44 Lysozyme C
(LysC) expression has been reported to specifically mark the macro-
phage compartment on the larvae yolk. Studies based on fluorescent
reporters would help scientists to elucidate, using in vivo monitoring,
inflammatory activation mechanisms and processes that induce
transformation from healthy to pathological adipose tissue.
Obesity is the single most significant risk factor for the develop-
ment of steatosis and zebrafish larvae develop steatosis. The inci-
dence and degree of steatosis were more severe in fish fed with a
high fat diet containing cholesterol (HFC). Hepatic lipid accumulation
in larvae increases the reliability of the HFC model for screening of
potential anti‐steatosis drugs.45
Another advantage of zebrafish larvae is the creation of transient
knockdown of gene expression through the use of morpholinos
(MOs),46 which allows rapid and effective study of gene function.
However, this is limited to the early stages of development. For
instance, larvae injected with an MO‐ApoC2 (Apolipoprotein C2)
exhibit an unabsorbed yolk phenotype. As result of reverse genetics
in zebrafish, apoC2, necessary for lipoprotein assembly in humans,
has been found to be essential during zebrafish larval develop-
ment.47 Fat mobilization in response to starvation and refeeding
have also been studied in zebrafish larvae. It was observed that,
when fish were starved for 4 days, neutral lipid depots were reduced
in all locations, until all fat materials were dissolved at 7 days of star-
vation. Refeeding for 4 days was sufficient to re‐establish neutral
lipid depots in the same locations as before starvation.24 These
observations are consistent with data in humans.
The zebrafish transgenic bioluminescence reporter Tg(pck1:Luc2)
is used for the identification of metabolically active drugs in the
gluconeogenesis process in response to the ‘feeding to fasting’ tran-
sition. The cytosolic phosphoenolpyruvate‐carboxykinase (PCK1)
promoter is induced when dietary carbohydrates are low. Its protein
catalyzes a regulatory step in gluconeogenesis in the liver and kid-
ney. PCK1 transcription is under insulin control during feeding condi-
tions and under glucagon, glucocorticoid and adrenaline control
during fasting conditions.48 These models can be used for further
investigation, and will be of particular importance in this age of
eating disorders and unhealthy diets.
3 | DIET ‐ INDUCED OBESITY MODEL IN
ADULT ZEBRAFISH
Animal models that closely mimic the human obese condition and
that allow the characterization of the metabolic pathways involved
in obesity development are of great interest. Most of them are diet‐
induced obesity models. These models recapitulate the gradual
weight gain that occurs in human populations as consequence of a
positive energy balance over years. Oka et al49 created the first
model of diet‐induced obesity in adult zebrafish in 2010. Zebrafish
overfed with high quantity of Artemia nauplii (a common live feed
used in zebrafish facilities) quickly developed a significant increase in
BMI. At the end of treatment, they exhibited hypertriglyceridemia
and hepatic steatosis.49 In this study, the authors did not explore the
long‐term effect of overfeeding. In our lab, we set up a model based
on long‐term exposure to a hypercaloric diet. We observed that zeb-
rafish acquired not only NAFLD, but also liver steatosis, which was
followed by development of fibrosis. Overfed fertile female zebrafish
developed less steatosis and were protected from the development
of fibrosis compared to overfed old females and all males.50 In
humans, different studies have demonstrated that non‐alcoholic hep-
atic steatosis is less common in women than in men and that the
prevalence of NAFLD is lower in women of reproductive age.50 This
is consistent with accumulating evidence for the role of inflammation
in the transition from NAFLD to NASH.51 Reproductive status is
associated with a generally lower level of inflammation while estro-
gen levels are high.50 This observation suggests the possibility of
using zebrafish in the evaluation of fibrosis (and other disease)
development during different reproductive stages, with the
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additional advantage that ovarian senescence in zebrafish is sponta-
neous.50,52
An additional constant feature in both models was the extremely
high penetrance of development of obesity and fatty liver. This is in
contrast with the rodent models, in which only a fraction of treated
animals developed these conditions.53,54 Interestingly, zebrafish were
fed in a meal‐feeding scheme that is very similar to human food
habits. A similar approach has also been proposed in rodents but the
use of diets that vary in nutrient composition, energy density, con-
sistency, and flavor gave rise to inconsistent data, with substantial
differences between experimental animals. Only when food was con-
tinuously made available, on a day and night basis, did obesity con-
sistently develop.55
Microarray analysis of liver tissue from zebrafish models of diet‐
induced obesity reveals a gene expression pattern that resembles
human NAFLD.56 Comparisons between DNA microarray analysis of
zebrafish and mammalian VAT revealed that genes involved in blood
coagulation, platelet activation and lipid metabolism are significantly
deregulated in obese zebrafish and mammals (mouse, rat and
human). Moreover, diet‐induced obesity in zebrafish responds to
caloric restriction and to treatment with natural compounds (green
tea, Campari tomato, resveratrol) by reducing BMI and modifying the
expression of genes related to obesity.57-59
Obesity is also positively associated with dietary factors such as
increased fat intake; in humans a high‐fat diet (HFD; >30% of
energy in fat) can easily induce obesity. This is also true in rats and
mice where a positive relation has been observed between the
amount of fat in the diet and body weight and fat gain.60,61 The role
of dietary lipids has also been assessed in zebrafish. Adult zebrafish
on a high cholesterol diet become obese and display an increased
deposition of adipocyte in the abdominal region.62 In order to
evaluate the effect of dietary fat on body fat accumulation, Meguro
et al63 compared the effect of four different diets (respectively
enriched in starch, gluten, corn oil, and lard) on zebrafish body fat
volume. No differences were observed in feed efficiency among
groups, but zebrafish treated with a diet enriched in fat (corn oil and
lard) displayed greater body fat volumes, consistent with previous
experiments in rodents. Indeed, in rodents the quantity of dietary
fat, but not the type of fat or the total energy intake, was shown to
be responsible of body fat accumulation.61 Differences in fat deposi-
tion and a predisposition to developing obesity‐related metabolic dis-
ease are described in human patients.64 Some patients exhibit so‐
TABLE 1 Transgene zebrafish models: (1) three different constructs of fluorescent reporters (GFP‐ DsRed‐ Luciferase); (2) liver specific
expression constructs obtained by insertion of fapb10a promoter sequence; (3) model of ectopic gene expression to induce obese phenotype
Zebrafish reporter
lines (1) Description Gene of interest References
Tg(hPPARγ-eGFP) Green fluorescent protein (GFP) under regulatory
control of peroxisome proliferator‐activated receptor
gamma (PPARγ)
PPARγ is a regulator of adipocyte differentiation.
Additionally, it is implicated in the pathology of
obesity, diabetes, atherosclerosis and cancer
42
Tg(lyz:Ds Red) Red reporter DsRED2 under control of lysozyme C
(LysC) gene expression
Lysozyme C (LysC) expression occurs in the macrophage
compartment, on the zebrafish larvae yolk. Marker of
the macrophage lineage
44
Tg(pck1:Luc2) Luciferase expression under the cytosolic
phosphoenolpyruvate‐carboxykinase (PCK1) promoter
PCK1 is a control gene for gluconeogenesis regulation.
The expression of this gene can be regulated by
insulin, glucocorticoids, glucagon, cAMP, and diet
48
Zebrafish liver‐
specific lines (2)
Transgene Gene of interest References
Tg(−2.8fabp10a:
gfp-gank)
Tg(−2.8fabp10a:
HBV.HBx-GFP)
Tg(−2.8fabp10a:
EGFP-yy1b)
The liver fatty acid binding protein (L‐FABP) allows liver
specific expression of green fluorescent protein (GFP)
Gankyrin (gank)
Hepatitis B virus X protein
Ubiquitous transcription factor Yin Yang 1 (YY1)
Modification of their expression is able to induce liver
steatosis in zebrafish
82-85
Tg(fabp10a:TETA-
cnr1,EGFP)
Conditional expression by use of a liver‐specific
(fabp10a) Tetoff transgenic system
Cannabinoid receptor 1 (CB1R): responsible for food
intake and weight gain and regulates several
pathological features associated with obesity in
mammals
86
Tg(fabp10a:TetON;
TRE:eGFP-kras)v12
Conditional expression by use of a liver‐specific
(fabp10a) Teton transgenic system
Upregulation of Ras signaling is able to determine the
accumulation of lipid droplets in zebrafish hepatocytes
and increase in the amount of TG
88
Zebrafish lipid
metabolism‐
related line (3)
Transgene Gene of interest References
Tg(krt4:
Has.myrAkt1)Cy18
AKT1 under the keratine4 promoter The ectopic expression of AKT1 in adipocytes is
responsible for the obese phenotype
87
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called “metabolically healthy obesity,” which is characterized by the
absence of metabolic abnormalities and comparatively less VAT and
low infiltration of macrophages into adipose tissue, as well as smaller
adipocyte cell size.65 This phenotype contrasts with the ‘metaboli-
cally unhealthy obese’ phenotype which exhibits a deleterious AT
distribution, with more visceral fat, larger adipocytes and evidence of
inflammatory processes.66 A comparison between zebrafish fed a
high‐fat diet (HFD) or a normal‐fat diet (NFD) showed that both
dietary regimens can induce a significant increase in BMI. An MRI
analysis of fat distribution revealed larger visceral and smaller subcu-
taneous adipocytes in HFD overfed fish compared to NFD obese
animals. HFD overfed zebrafish also showed significantly elevated
blood glucose, triglyceride and cholesterol levels and a prominent
accumulation of lipids in liver and muscles.67 These data suggest
that, depending on the type of diet and food regimen, zebrafish
could resemble both the “healthy” and “unhealthy” obesity pheno-
types and provide an interesting model for studies of the regulatory
mechanisms involved in these pathways, as well as the metabolic
states.67
Recently, a model of T2DM in zebrafish has been established.68
To develop a diet‐induced obesity model with hyperglycemia, fish
were fed with an increased quantity of a commercial food. In terms
of calories, each overfed animal was provided with 408 calories/day
vs. the 150 calories/day used by Oka et al.49 This regimen is able
to very quickly induce an increase in BMI, adipose tissue volume
and plasma triglyceride, as well as an impaired glucose tolerance,
increased insulin production and an increased β‐cell mass, consis-
tent with an insulin resistance model of T2DM. Remarkably, this
model of T2DM is responsive to antidiabetic drugs (metformin and
glimepiride) and has transcriptomic pathways similar to human dis-
ease.69
All the cited models of diet‐induced obesity in zebrafish raise the
possibility using this animal to study the development of obesity and
obesity‐related disease in a system that resembles the human/mam-
malian pathology. Unfortunately, a standardized diet for common
application in zebrafish has not yet been formulated.70 As reported
in Table 2, several diet regimens differing in calories, fat content and
composition have been used so far. Diets that vary in their nutrient
composition give rise to differences in energy intake, body composi-
tion and AT deposition. In addition to complications arising from
variable diets, husbandry conditions can also affect energy expendi-
ture and, as a consequence, caloric balance.55,70
4 | ZEBRAFISH MUTANTS AS A MODEL OF
OBESITY
Mutant fish are currently used in order to study obesity‐related dis-
ease. Zebrafish mutants that carry mutations in genes involved in AT
storage and in mobilization are good tools for further characteriza-
tion of cellular and molecular mechanisms involved in fat accumula-
tion, in order to identify molecular targets and approaches needed
to treat or prevent obesity (Figure 2).
The vizzini mutant carries a null mutation in the GH1 gene that
encodes for an endocrine factor produced by the anterior pituitary
gland, which serves to synchronize growth and to regulate lipid
metabolism.71 As a consequence, animals display an increase in AT
and the inability to properly mobilize stored fats. The same
TABLE 2 Different protocols of diet‐induced obesity (DIO) in zebrafish and the resultant phenotype
Model of DIO
zebrafish Feeding
Observation
period Phenotype
Oka et al49 60 mg/cyst/d
Artemia Nauplii
8 wk Obesity, increased plasma triglyceride, alteration in genes involved in
lipid metabolism and coagulation
Meguro et al63 LF (low fat diet)
Otohime B2 + starch or gluten
HF (high fat diet):
Otohime B2 + lard or corn oil
6 wk Increased body fat volume and body fat volume ratio in HF‐fed
animals
Forn‐Cunì
et al92
Artemia Nauplii +fish chow (4 meal/d) 8 mo Obesity, steatosis, liver gene expression similar to human NAFLD
Turola et al50 60 mg/cyst/d
Artemia Nauplii
24 weeks Obesity, liver steatosis and fibrosis
David et al62 HCD (high cholesterol diet): Pelleted fish
food + 6% cholesterol
6‐8 wk Increased BMI, obesity, lipid droplets (LDs) in intestinal microvilli
Zang et al68 120 mg/d
Otohime B2
(commercial fish food)
8 wk Insulin resistant T2DM, with glucose intolerance and insulin
overproduction
Landgraf et al67 NFD (normal fat diet):
60 mg/cists/d
Artemia Nauplii
HFD (high fat diet):
5 mg/cists/d
Artemia Nauplii + 30 mg egg yolk powder
8 wk Increased body weight and AT mass in both diets
Hyperglycemia and ectopic lipid accumulation in HFD fed fish
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characteristics were observed in GH‐deficient and GH‐insensitive
mouse. Another zebrafish mutant used in studying obesity is
cyp2r1−/−, which has a premature stop codon in the CYP2R1
gene.72 Like the vizzini mutants, cyp2r1−/− zebrafish displayed
excessive VAT accumulation, mainly due to an increase in number
(but not size) of adipocytes and significantly increased total lipids.
Supplementation with 1,25(OH)2D3 reverses the defect caused by
the mutation, suggesting that vitamin D3 is an important regulator
of lipid metabolism.72 Accordingly, mice defective in the vitamin
D/vitamin D receptor system display a lean phenotype, and resis-
tance to HFD‐induced obesity.73 In addition, the lepr and mc4r
genes are obesity‐related. Mutations of these genes in zebrafish,
achieved via the CRISPR/Cas9 technique, have shown that the
adult lepr−/− and mc4r−/− individuals, but not post‐juvenile fishes,
displayed characteristics of obesity phenotypes like higher weight
and body fat percentages, as well as significantly impaired glucose
tolerance.74 MC4R and leptin protein are involved in feeding and
metabolism, and seem to be conserved between teleost fish,
including zebrafish, and mammals.75,76 In particular, MC4R medi-
ates the melanocortin system, playing an important role in the
evolution of the diverse array of reproductive, growth, and feeding
strategies in teleost fish.77 Experimental blockade of MC4R by
overexpression of agouti‐related protein (AgRP), or mutations in
pro‐opiomelanocortin (POMC), an endogenous agonist of AgRP,
increased body weight, body fat and adult length in zebrafish, as
well as and levels of triglyceride.76,78,79 The pathway driven by
the leptin hormone is also known to be implicated in energy
homeostasis and obesity regulation, and to be active in different
circuits in the brain involved in regulation of food intake, energy
balance and glucose homeostasis.
Leptin deficiency in mammals (due to mutation in both leptin or
leptin receptor genes) is a well‐known cause of obesity, diabetes and
infertility, while leptin replacement in leptin‐deficient individuals
ameliorates obesity.38 In zebrafish, a mutant for the leptin receptor
(leprsa1508/sa1508) has been isolated through screening for mutations
after N‐ethyl‐N‐nitrosourea (ENU) mutagenesis.38 In contrast to data
collected in rodents, adult zebrafish with a mutated leptin receptor
do not exhibit increased adiposity. Indeed, no differences in body
composition and amount of fat were observed between wild type
and leprsa1508/sa1508 zebrafish, irrespective of whether they were
overfed or fed on a standard diet. On the other hand, mutant zebra-
fish displayed increased levels of insulin mRNA, alterations in glucose
homeostasis, increased β‐cell mass, and altered wound healing, but
not insulin resistance.38 Leptin receptor‐deficiency (knockout) was
also established in medaka.80 As in the lepr−/− and mc4r−/− zebrafish
models,74 in the lepr−/− medaka model, the post‐juvenile and adult
stages responded differently to food intake. In the post‐juvenile
stage, the mutant exhibited a higher growth rate, indicating that
increased intake of food was effectively utilized for growth from
post‐hatching until the adult stage, and not for lipogenesis. In con-
trast, at the adult stage, the increased food intake led to excessive
fat deposits only around the abdominal viscera, with no alteration of
TAG in liver, skeletal muscle or in the bloom. These data suggest
that zebrafish could also be used to study the regulation of food
intake by neuroendocrine modulators and the effects on fat accumu-
lation leading to obesity.
F IGURE 2 Zebrafish mutant models of obesity and fat distribution. Several mutant models in zebrafish are available in order to study the
pathways involved in obese phenotypes. The signaling of different models is shown in the figure: (A) vizzini, (B) cyp2r1−/−, (C) mc4r−/−, (D)
lepr−/−, (E) leprsa1508/sa1508, (F) PLXND1-null. The main effects of these pathways are connected to regulation of lipid metabolism, control of
energy balance, distribution of body fat and/or sensitivity to insulin
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Another protein in zebrafish not directly correlated with obesity,
but with body fat distribution, is Plexin D1. Inhibition of Plexin D1
(PLXND1) led to different effects in zebrafish and mouse models of
obesity.81 Indeed, PLXND1 knockout mice died at birth, while
PLXND1-null zebrafish were vital, allowing the study of gene ablation
in adult animals. In zebrafish, PLXND1 regulates body fat distribution
by determining the growth characteristics of VAT. The absence of
PLXND1 results in a preferential expansion of subcutaneous adipose
tissue (SAT) in response to HFD, and thus leads to further exacerba-
tion of altered body fat distribution, decreasing the VAT:SAT ratio.
Thus PLXND1 deficiency protects zebrafish from HFD‐induced insu-
lin resistance and glucose intolerance, in accordance with association
data from humans.81
5 | TRANSGENIC ZEBRAFISH IN THE
STUDY OF OBESITY ‐RELATED DISEASE
In order to study obesity‐related disease, transgenic zebrafish dis-
playing altered accumulation of AT and liver steatosis were devel-
oped. The goal of these models was to mimic a specific pathology
(ie, liver steatosis) to characterize the pathway involved in the dis-
ease and to study its downstream effects. Three transgenic models
for studying liver steatosis and NASH were developed in zebrafish
by Her et al. In these models gankyrin, HBx and YY1 were
expressed, associated with GFP, under the liver‐specific L‐FABP 2.8
promoter.82-85 All these three models in adult zebrafish displayed
hepatic steatosis due to increased transcriptional activity of lipogenic
genes and subsequent increased hepatic de novo FFA synthesis and
lipid accumulation in hepatic cells. This initiated apoptosis, lipid oxi-
dation and reactive oxygen species (ROS), leading to further devel-
opment of liver damage. Interestingly, miRNA, known to be
associated with NASH, was also found to be deregulated in trans-
genic zebrafish expressing gankyrin.82 A similar phenotype, charac-
terized by hepatic steatosis and alterations in the lysogenic gene
SPREBP-1c, the lipogenic enzyme involved in fatty acid synthesis,
transporters, and lipid storage genes, was also observed in the condi-
tional transgenic zebrafish [Tg(-2.8fabp10a:-Tetoff-CB1R:2A:eGFP)],
without treatment with doxycycline.86 Despite the increased de
novo synthesis of FFAs and the high rate of lipid accumulation in
the liver, no obesity has been observed in these models. Gankyrin
and HBx transgenic fish display emaciation and a declining growth
rate, probably as a consequence of liver disease.82,83
In contrast, a severe obese phenotype has been observed in
adult Tg(krt4:Has.myrAkt1)Cy18 zebrafish, which express the human
AKT1 gene under the keratin 4 promoter.87 The ectopic expression
of AKT1 in adipocytes is responsible for the obese phenotype. AKT1
is known to act upstream of PPARγ and CEBPα in modulating adipo-
genesis. Transgenic animals display hyperplastic growth of adipo-
cytes, increased total triglyceride content, glucose intolerance, fat
tissue accumulation in dorsal muscles, gills, and tail, neutrophil infil-
tration and osteoporosis caused by adipocyte infiltration. Moreover,
Tg(krt4:Has.myrAkt1)Cy18 zebrafish also displayed a reduced activity
(observed by swimming behavior assay) and a short life span.87 As
reported by Yao et al88 transgenic zebrafish that conditionally acti-
vate Kras (Tg(fabp10a:TetON;TRE:eGFP-kras)v12) developed intensive
accumulation of lipid droplets in hepatocytes and increased amounts
of TG. Taken together, these data suggest not only that the ectopic
transgenic modification of Ras and/or Akt expression is able to cause
NAFLD in the liver, but also that these pathways could be investi-
gated as possible therapeutic targets for blocking the progress of
liver damage.
The availability of these stable transgenic models provides a
promising tool for studying the molecular pathways involved in liver
disease and a simple and reliable method for assessing drug treat-
ment efficacy.
6 | ROLE OF MICROBIOTA IN OBESITY
CONTROL
In addition to various other causal agents, alterations in intestinal
microbiota have recently been linked to the induction and progres-
sion of liver damage.89 Gut flora alterations also include overproduc-
tion and release into the circulation of bacterial endotoxins
(lipopolysaccharides, LPS). Evidence suggests that the variation (in-
crease in the number and/or alteration in the type of bacteria) in the
intestinal microbiota can increase gut permeability and LPS plasma
levels.90 The liver transcriptomic response to LPS has been evaluated
in overfed zebrafish.91 The host inflammatory response to gut micro-
biota is emerging as an important factor in the development of
NASH.92-96 Obese zebrafish showed a small increase in the expres-
sion of pro‐inflammatory genes, but they are not able to completely
activate the entire inflammatory pathway involved, probably due to
the basal chronic inflammation process induced by metabolic factors
such as obesity.92 Differences in and modifications to microbiota
through probiotic or prebiotic drugs are able to predict the respon-
siveness to weight‐loss diets and pharmacological treatment in obese
individuals.97,98 In order to understand the correlation between
intestinal microbiota and obesity and obesity‐related conditions, the
use of germ‐free animals is very useful. In 2008, a method for gener-
ating gnotobiotic wild‐type and/or genetically manipulated zebrafish
for the study of symbiotic/commensal host‐bacterial relationships in
the vertebrate digestive tract was developed.99 The relative ease of
obtaining suitable experimental conditions, compared to mouse
model experiments, together with the possibility of monitoring bio-
logical processes in vivo and the similarity to mammalian microbiota
composition, made germ‐free zebrafish an attractive tool for study-
ing gut microbiota. Dietary lipid content has been shown to influ-
ence the gut microbiome in adult zebrafish, suggesting that it is
strictly related to adiposity and obesity. The exposure of adult zebra-
fish to different amounts of lipid (high [HFD], medium [MFD], low
[LFD]) shifted the philotype composition of the gut microbiome by
reducing community diversity in the HFD group, and affected the
transcription of genes involved in appetite control and in cholesterol
metabolism suggesting an important role for gut microbiota in
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obesity.100 Notably, supplementation of the diet with the probiotic
Lactobacillus rhamnosus decreases total body cholesterol in zebrafish
fed with HFD and MFD,100 suggesting new possibilities in the treat-
ment of obesity and high‐fat diet‐related metabolic disorders through
manipulation of gut microbiota.100,101 These data suggest that the
gnotobiotic zebrafish model could be a useful tool for exploiting the
functions of intestinal microbiota in the control of obesity and its
related diseases and to test how modulation of microbiota could
affect the pathology.
7 | CONCLUSION
Zebrafish is emerging as a relevant system in the study of obesity
and obesity‐related disorders. Several mutant and transgenic lines
that display alterations in AT deposition and mobilization, and in the
regulatory brain circuits involved in its homeostasis, have been set
up in larvae and adult zebrafish. These models are very useful to
characterize the mechanisms and pathways involved in the diseases
and to test new pharmacological and therapeutic approaches. How-
ever, they fail to mimic the initial stage of obesity development;
indeed, human obesity is mostly a consequence of a positive energy
balance, primarily due to excessive food intake. The animal models
that best reflect the human pathology are dietary‐induced models.
Interestingly, zebrafish respond well to diet modification. Exposure
to hypercaloric and high fat diets quickly induces obesity and obe-
sity‐related disease and activates metabolic pathways very similar to
their human counterparts. Unfortunately, the lack of standardized
feeding protocols and housing conditions leads to variation in the
results obtained by diet manipulation and is still a great limitation of
these models.
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